Biocryst Pharmaceuticals (BCRX) EBT (2010 - 2026)

Biocryst Pharmaceuticals has reported EBT for 17 years, with the latest figure at -$720.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 95193.4% year-over-year to -$720.8 million; the trailing twelve-month figure through Mar 2026 stood at -$454.2 million (down 787.37% YoY), and the FY2025 full-year result was $267.4 million, up 407.51% from the prior year.
• EBT for Q1 2026 stood at -$720.8 million, down from $248.0 million in the prior quarter.
• The five-year high for EBT was $248.0 million in Q4 2025, with the low at -$720.8 million in Q1 2026.
• Historically, EBT has averaged -$59.5 million across 5 years, with a median of -$35.8 million in 2023.
• Annual changes were most pronounced in 2025 — EBT surged 1054.24% — and 2026, when it slumped 95193.4%.
• Biocryst Pharmaceuticals' EBT stood at -$71.5 million in 2022, then grew by 11.62% to -$63.2 million in 2023, then jumped by 58.85% to -$26.0 million in 2024, then surged by 1054.24% to $248.0 million in 2025, then sank by 390.63% to -$720.8 million in 2026.
• The last three EBT figures came in at -$720.8 million (Q1 2026), $248.0 million (Q4 2025), and $12.1 million (Q3 2025), per Business Quant data.